Oscar Sanchez

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

AMAG Pharma USA, Inc. engages in the provision of pharmaceutical products to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, government entities, and physicians. The company was founded by Victor M. Hermelin in 1942 and is headquartered in Waltham, MA.

Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation.

Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada.

Charles River Laboratories Edinburgh Ltd. provides drug development services. The company is headquartered in Tranent, the United Kingdom.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Smith & Nephew, Inc. develops and markets medical devices. Its products include television cameras and monitors, endoscopes, arthroscopes, orthopedic hand owered instruments, fiber optic illumination systems, laparoscopes, and surgical instruments. The company was founded on November 27, 1975 and is headquartered in Memphis, TN.

Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA.

Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ.

American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021.

Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation.

Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina.

Founded in 2015, DalCor Pharma UK Ltd. is a subsidiary of DalCor Pharmaceuticals Canada, Inc. The company is based in Leatherhead, UK. The British company engages in research and experimental development on biotechnology.

Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.

Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA.